Short Communication

Encapsulated Salmon Polar Lipids Modestly Reduce Postprandial Platelet Sensitivity to PAF

and Thrombin in Healthy Adults: A Pilot Study.

Ronan Lordan [1,2,3,4,†,*], Alexandros Tsoupras [1,5,†], Phil Jakeman [6,7], and Ioannis Zabetakis [1,2,7*]

[1] Bernal Institute, University of Limerick, V94 T9PX, Limerick, Ireland.

[2] Department of Chemical Sciences, University of Limerick, V94 T9PX, Limerick, Ireland.

[3] School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland (RCSI)

University of Medicine and Health Sciences, D02 VN51 Dublin, Ireland.

[4] FutureNeuro Research Ireland Centre for Translational Brain Science, RCSI University of

Medicine & Health Sciences, D02 YN77 Dublin, Ireland.

[5] Hephaestus Laboratory, School of Chemistry, Faculty of Sciences, Democritus University of

Thrace, Kavala University Campus, St. Lucas, 65404 Kavala, Greece.

[6] Department of Physical Education and Sport Sciences, University of Limerick, V94 T9PX,

Limerick, Ireland.

[7] Health Research Institute (HRI), University of Limerick, V94 T9PX, Limerick, Ireland.

[*] Correspondence: ronanlordan@rcsi.com

[†] These authors contributed equally to this research.

Abstract:

The postprandial effects of a novel food-grade extracted salmon polar lipids (SPL) supplement against platelet-activating factor (PAF) and thrombin-induced platelet aggregation in a human pilot study was evaluated. This study was double-blinded, crossover, and placebo controlled in design. Five healthy volunteers completed 4 h time-course trials on 5 separate days. Blood was drawn at baseline before subjects consumed a standardized breakfast with one of the following treatments: a low-dose (0.25 g) or a high-dose (0.5 g) of SPL encapsulated within a stomach resistant capsule (LDSR and HDSR respectively) or a non-resistant capsule (LDSNR and HDSNR, respectively), or placebo capsules containing food-grade glycerin (0.5 g; Placebo). Blood was analyzed at 1 h intervals for 4 h. Among the treatments tested, the high-dose non-resistant capsule (HDSNR) produced the clearest postprandial effects, inducing significant increases in EC_{50} (reduced platelet sensitivity) for PAF at 2–3 h and for thrombin at 3–4 h post-ingestion. Smaller or delayed effects were observed with the high-dose resistant capsule (HDSR), while low-dose formulations produced minimal changes. Postprandial plasma glucose, lipid profile (TC, HDL-C, LDL-C, TG), fibrinogen, prothrombin time, and activated partial thromboplastin time remained unaffected across all trials. This pilot study provides the first in vivo indication that SPL supplementation may modestly attenuate platelet responsiveness to both PAF and thrombin without altering standard haemostatic or metabolic biomarkers. Larger controlled studies are warranted to confirm these preliminary findings and define optimal dosing and formulation strategies.

Keywords: polar lipids; platelet function; platelet-activating factor; thrombin; nutraceuticals; fish oil; postprandial; haemostasis; salmon oil; postprandial

1. Introduction

Low-grade or systemic inflammation contributes to the onset of atherosclerosis and subsequent cardiovascular diseases (CVD) [1-4]. Activation and aggregation of platelets contribute to the 'crosstalk' between various cells including endothelial cells and leukocytes engaged in the inflammatory development of atherosclerosis and atherothrombotic events [5-7]. Platelet agonists mediate platelet activation and aggregation. Of these, platelet-activating factor (PAF) and thrombin are among the most potent [5,8,9]. PAF activates various pathophysiological signaling pathways in response to inflammatory stimuli that negatively affect cardiovascular risk factors [10,11]. Thrombin on the other hand, is a procoagulant and pro-inflammatory serine protease that participates in coagulant catalytic processes as well as the activation of other cell types in several pathophysiological processes [8,9,12], including atherosclerosis [12]. PAF and thrombin are known to enhance the expression of cell adhesion molecules that induce secretion of pro-inflammatory cytokines, an inflammatory response in atherosclerotic plaques, proliferation of aortic smooth muscle cells and vascular lesion at sites of injury [2,12,13].

The inhibition of PAF and thrombin related pathways offers a potential therapeutic strategy to target thrombosis and inflammatory responses that underpin the atherosclerosis and inflammatory disorders [2,13,14]. It is recognized that some dietary patterns and their components have the potential to reduce levels of specific risk factors for CVD, including the reduction of inflammation [15,16]. CVD-related PAF and thrombin pathways are affected by the diet either favorably, by positive dietary behaviors such as those attributed to the Mediterranean diet, or detrimentally by dietary behavior related to the Western diet [17]. The Western diet is characterized by energy-rich, ultra-processed foods that cause exaggerated postprandial increases in plasma lipids and glucose leading to hyperglycemia and hyperlipidemia [18]. These elevations lead to

excess pro-inflammatory reactions and activated platelets and immune cells [19,20]. Indeed,

postprandial platelet activation and hypercoagulability are major risk factors for CVD [21], of

which the PAF pathway can be modulated by dietary components postprandially [22].

Fish oils, particularly omega-3 polyunsaturated fatty acids (n-3 PUFA) have been a

promising but contentious area of research due to their putative cardioprotective effects [23,24].

Food-grade extracts from sustainable sources are potential candidates for the development of novel

cardioprotective nutraceuticals, which are important for improving underlying health conditions

and overall well-being in aging populations characterized by increased risk of non-communicable

diseases [25,26]. In previous studies, it has been demonstrated that polar lipids extracted from Irish

organic farmed salmon (*Salmo salar*) possess strong antithrombotic properties against platelet

aggregation *in vitro* relating to the PAF and thrombin pathways *in vitro* [25,27,28]. Studies have

also shown that salmon oil may favorably affect metabolic syndrome through phospholipid

remodeling, inhibiting insulin resistance, and reducing inflammatory factors [29]. Indeed, the

consumption of fish and fish oil supplements may affect platelet function and cardiovascular health

[30-32], although there is a dearth of postprandial investigations assessing the biological effects of

marine-sourced polar lipids. This pilot study investigates the temporal pattern and magnitude of

the antiplatelet effects of food-grade extracted salmon polar lipid ingestion (SPL) postprandially

in a pilot study of five healthy human subjects over a 4 h period.

2. Materials and Methods

2.1. Materials and instrumentation

All glass and plastic consumables, reagents, and solvents were of analytical grade and were

purchased from Fisher Scientific Ltd (Dublin, Ireland). 18G Insyte™ cannulas were purchased

from Becton Dickinson Ltd. (UK). A CARESITE® extension set, 0.9% w/v saline, and Omnifix®

syringes with varied volumes were purchased from Braun Medical Ltd. (Dublin, Ireland).

Tegaderm™ transparent protective dressings were acquired from 3M Health Care (Neuss,

Germany). Evacuated sodium citrate 9 NC, EDTA KE, glucose FE, and serum gel Z S-monovettes

for blood sampling were purchased from Sarstedt Ltd. (Wexford, Ireland). The *ex vivo* platelet

aggregation bioassay was carried out on a Chronolog-490 two channel turbidimetric platelet

aggregometer (Havertown, PA, USA), coupled to the accompanying AGGRO/LINK software

package. All platelet aggregation consumables were purchased from Labmedics LLP (Abingdon

on Thames, UK). Standard PAF, thrombin, and BSA were purchased from Sigma Aldrich Ltd.

(Wicklow, Ireland). Centrifugations were carried out on an Eppendorf 5702R centrifuge

(Eppendorf Ltd Stevenage UK). Spectrophotometric analysis was carried out on a Shimadzu UV-

1800 spectrophotometer (Kyoto, Japan).

2.2. Isolation and encapsulation of food-grade SPL

A sustainable marine source was chosen for these studies; Irish organic farmed salmon

(*Salmo salar*). Fresh salmon fillets were homogenized mechanically by blender and total lipids

(TL) extracted and further separated into neutral lipid (NL) and polar lipid fraction (SPL) in

accordance with EU legislation for food-grade based extractions of fish oil (consolidated Directive

2009/32/EC: https://eur-lex.europa.eu/legal-content/en/ALL/?uri=CELEX:32009L0032)   as

previously described [25]. Solvents were evaporated from samples using flash rotary evaporation

and lipid samples transferred to small vials and remaining solvents evaporated under a stream of

nitrogen. The acquired SPL extracts were weighed and encapsulated under a stream of nitrogen

into gelatin-coated capsules of two types: stomach non-resistant capsules (SNR) and stomach

resistant capsules (SR). Placebo capsules were prepared containing only glycerin. All capsules

were prepared external (Propak Health Ltd., Finglas, Dublin, Ireland) to the university and were

tested for microbial safety, heavy metals, pesticides, and various other potentially harmful

constituents (Eurofins Food Testing Ireland Ltd., Dungarvan, Co. Waterford, Ireland).

2.3. Study population

This study was conducted according to the guidelines laid down in the Declaration of

Helsinki, approved by the Ethics Committee of the Faculty of Science and Engineering of the

University of Limerick and registered with ClinicalTrials.gov NCT03603769. Following written

and informed consent, six participants completed a routine clinical, haematological, biochemical,

and anthropometrical screening session with a general practitioner to assess suitability. Exclusion

criteria were smoking, following a diet regime or special diet, diagnosis of hypertension, metabolic

or endocrine disease, gastrointestinal disorders, blood clotting disorders, dyslipidaemia, or a recent

history of medical or surgical events. One volunteer that initially participated and was deemed

eligible for the study had to terminate their participation due to personal commitments. A total of

five participants (n = 5) completed all aspects of the study. Recruitment, screening, and treatment

allocation occurred as outlined in the CONSORT flow diagram (Figure 1). The baseline

characteristics of the five participants are provided in Table 1 and Table 2 in the supplementary

files. Healthy participants were selected for this pilot study for several reasons, including safety

assessment and tolerability of an acute dose of the supplement before testing in a clinical

population. Furthermore, this approach allowed for assessment of the capsule under controlled

baseline physiology in participants with stable platelet profiles in the absence of medication, which

would allow for more clear detection of physiological changes directly attributable to the

intervention.

148   **Fig. 1.** CONSORT flow diagram of participant involvement and trial layout

2.4. Study protocol

In a randomized, double-blind design, each subject completed five trials on separate days at least 14 days apart from each other. Three days before the trial and throughout the entire trial period, volunteers were instructed to follow Irish national dietary guidelines [33], which allows moderate consumption of fish (once or twice per week). The participants were asked to abstain from alcohol, avoid excessive exercise, and sleep at least 7 h/day throughout the study. After fasting overnight (10–12 h), each participant arrived at the laboratory at 09:00 and were seated in a phlebotomy chair and allowed to rest for five minutes. A certified clinical nurse then proceeded to fit the volunteer with a cannula. A 20 G cannula (BD Insyte™) was inserted into the median cubital vein, which was attached to a CARESITE® extension set. The cannula was held in place with a Tegaderm™ transparent protective dressing.

An initial 1.5 mL of blood was drawn through the cannula using a 3 mL syringe. This was discarded to fill the line with blood. A further 21.4 mL of blood was drawn using a 25 mL Omnifix® syringe. The line was then flushed with 10 mL of 0.9% w/v saline using a 10 mL Omnifix® syringe. The collected blood was then transferred into 5 S-monovettes: 1) 8.2 mL sodium citrate 9 NC S-monovette; 2) 2.9 mL sodium citrate 9 NC S-monovette; 3) 2.7 mL EDTA KE S-monovette; 4) 2.7 mL Glucose FE S-monovette; 5) 4.9 mL Serum Gel Z S-monovette (Sarstedt Ltd., Wexford, Ireland). All monovettes were appropriately labelled and placed in clinical sample transportation boxes in order to be sent to the appropriate laboratory for further analysis; monovette 1 from each participant was immediately sent to the laboratories of the Department of Biological Sciences of UL for analysis, while monovettes 2-5 were kept in the transportation box and sent to the Haematology and Biochemistry Laboratory of University Hospital Limerick for analysis immediately after the 5th and final blood draw.

Following the initial baseline blood draw at approximately 09.05, the participant was fed a

standardized breakfast, namely porridge, which was made with boiling water as per the

manufacturer's instructions (Flahavan's Quick Oats® original with the following nutritional value:

Energy 637 kJ/ 150 kcal; Fat 2.6 g; of which saturated 0.4 g; Carbohydrates 25 g; of which sugars

7.3 g; Fibre 3.5 g; Protein 5.2 g; Salt 0.03 g).

Once breakfast was consumed, randomized and double-blind administration of capsules of

different types and dose, according to the aforementioned trials design took place. Each capsule

was administered with a glass of water. The capsule compositions were as follows:

(1) LDSNR, low-dose stomach non-resistant capsule containing 0.25 g of SPL

(2) HDSNR, high-dose stomach non-resistant capsule contained 0.5 g of SPL

(3) LDSR, low-dose stomach resistant capsule contained 0.25 g of SPL

(4) HDSR, high-dose stomach resistant capsule contained 0.5 g of SPL

(5) Placebo stomach release capsule containing 0.5 g of food-grade glycerin

Blood samples were subsequently obtained by repeating the steps for blood sampling every

h for the next 4 h. The citrated blood samples were sent at each time of blood withdrawal to the

Department of Biological Sciences of UL for platelet aggregometry testing and the remaining

blood tubes were stored in a blood transportation box to be taken to the haematology and

Biochemistry laboratories of University Hospital Limerick, where several biological parameters

were assessed. After each blood draw, the cannula was flushed with saline (0.9 % w/v). During

the study, participants were encouraged to drink at least 50 mL of water following every blood

draw and were encouraged to keep their cannulated arm supported, still, and warm, while

remaining seated.

2.3. Ex vivo human platelet-rich plasma (hPRP) aggregation assays

The platelet aggregation response to PAF and thrombin was conducted as previously

described with some modifications [34]. Briefly, standard solutions of PAF and thrombin were

prepared ranging from 2.6 x 10^{-8} to 2.6 x 10^{-5} mol/L BSA (2.5 mg BSA/mL saline (0.9%)) PAF

and 0.01-0.4 U/mL active thrombin in saline (0.9%). hPRP was isolated from anticoagulated

(sodium citrate 0.106 mol/l) blood samples by centrifugation at 194 x g for 18 min at 24 °C, the

supernatant hPRP transferred to polypropylene tubes at room temperature. Platelet-poor plasma

(PPP) was obtained by further centrifugation at 1465 x g for 20 min at 24°C and supernatant PPP

transferred to polypropylene tubes at room temperature for aggregation bioassay. Then an

aggregation bioassay was conducted. Briefly, PPP (250 μL) and hPRP (250 μL) were pipetted into

separate glass aggregometer (Chronology, Havertown, PA, USA) cuvettes at 37 °C. Platelet

aggregation, detected by change in light transmission at a fixed wavelength (620 nm) in the

presence of increasing concentration of agonist generated aggregation curves from which the

concentration of agonist that induces maximum-reversible platelet aggregation could be

determined. The serial reduction of either PAF or thrombin required to induce maximum-

reversible platelet aggregation revealed a linear response between 20%-80% of maximum and the

concentration of agonist that induced 50% platelet aggregation, i.e., the EC_{50} value. The EC_{50} value

represented platelet sensitivity to the agonist. The higher the EC_{50} value the lower the sensitivity

of the platelet to the agonist to either PAF or thrombin.

2.2. Biochemical and haematological measuements

The University Hospital Limerick (Limerick, Ireland) undertook all biochemical and

haematological analyses. Chemiluminescent magnetic microparticle immunoassay (CMIA)

technology (Abbott Architect C16000 clinical chemistry analyser®, Abbott Ltd., Dublin, Ireland)

was employed to measure glucose, triglycerides (TG), total cholesterol (TC), high-density

lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and C-reactive

protein (CRP) in each blood sample. Prothrombin time (PT) activated partial thromboplastin time

(APTT), fibrinogen and the international normalized ratio (INR) were measured by

electromechanical detection (Stago STA-R Evolution® analyser, Diagnostica Stago, Wicklow,

Ireland).

2.2. Statistical analysis

This pilot study employed a randomized, double-blind, placebo-controlled crossover

design with five conditions and repeated sampling (baseline plus four hourly draws). The a priori

power calculation indicating ~83% power to detect a 1-SD difference assumed a large treatment

effect and favorable assumptions regarding between- and within-subject variability. Because

repeated measures collected over a short time window are often highly correlated, the effective

statistical power in this small sample (n = 5 completing all conditions) is likely lower than the

nominal estimate. Accordingly, this study was primarily intended as a pilot to assess safety,

tolerability, and variance characteristics rather than to provide definitive evidence of efficacy. All

data are presented as a mean percentage EC_{50} with standard error mean . The percentage change

in EC_{50} from baseline and the temporal percentage incremental change $((\Delta Ct\text{-}0/C0))$ in EC_{50} from

baseline were calculated for each time point for each treatment, which are depicted in Figures 2

and 3.

For analysis of the PAF EC_{50} data, there were no outliers as shown by examination of

studentized residuals for values greater than ± 3. The data was assessed for normality distributed

($p > 0.05$) apart from 1h LDSNR and 3h of HDSNR ($p < 0.05$) as assessed by Shapiro-Wilk's test.

Mauchly's test of sphericity indicated that the assumption of sphericity was not met for the two-

way interaction, $\chi^2(2) = 67.6$, $p = 0.003$ and Greenhouse-Geisser correction applied. A two-factor

analysis of variance (ANOVA; treatment x time) was used with repeated measures on the factor

time. The Bonferroni post hoc correction was applied where significant interaction was evident.

For PAF ΔAUC, outliers were assessed via boxplots (values > 1.5 box-lengths). Shapiro–

Wilk's test indicated normal distribution for all treatment conditions except HDSNR, which

showed marginal deviation ($p = 0.048$). Mauchly's test indicated that the assumption of sphericity

was met; therefore, no correction was applied ($\chi^2(9) = 12.52$, $p = 0.281$). Significance was set at p

< 0.05, and effect sizes are reported as partial eta squared (η_p^2). Post-hoc comparisons were

conducted using pairwise contrasts with adjusted p-values where appropriate. All EC_{50} outcomes

are presented as percentage change from baseline (mean $\pm$ SEM). Statistical results in text are

reported as mean differences with 95% confidence intervals (CI)

For thrombin EC_{50}, data screening identified no outliers based on studentized residuals

(±3). Normality and sphericity were assessed as described for PAF; sphericity was violated for the

treatment $\times$ time interaction ($\chi^2(2) = 67.6$, $p = 0.003$), and Greenhouse–Geisser correction was

applied. Thrombin ΔAUC analysis identified one outlier in the HDSR condition using the boxplot

criterion (>1.5 $\times$ IQR). AUC data met normality assumptions, and sphericity was not violated;

therefore, no correction was required. Repeated-measures ANOVA was used for both EC_{50} and

AUC analyses, with post-hoc pairwise comparisons performed where appropriate. All analyses

were conducted using Microsoft Excel (v16.1.1) and SPSS (v30.0.0).

3. Results

3.1. Postprandial effect of SPL on plasma levels of CRP, glucose, and lipid levels

Baseline plasma biomarkers of the lipid profile TG, TC, HDL-C, LDL-C, glucose, and CRP were within the normal range prior to the study for all participants (Table S1) and no significant change in these biomarkers was observed following ingestion of the SPL or placebo capsules within the timeframe assessed (Figure S1). Cumulative ingestion and exposure should be assessed in a dietary study.

3.2. Postprandial effect of SPL on biomarkers of coagulation

Baseline plasma fibrinogen, PT, INR, and APTT were within normal range for all participants prior to the study (Table S2). Furthermore, these parameters did not differ significantly from baseline following ingestion of the SPL or placebo capsules within the timeframe assessed but further study is required for cumalitve exposure (Figure S2).

3.3. Postprandial effect of SPL on platelte sensitivity to PAF

Figure 2A depicts the temporal change in PAF EC_{50} for each treatment following ingestion when compared to baseline levels (t = 0). The placebo did not significantly affect PAF EC_{50} at any time during the 4 h postprandial period.

Analysis of ΔPAF EC_{50} revealed a significant treatment × time interaction, indicating that the temporal pattern of change differed across treatments ($F(16, 64) = 3.30$, $p \leq .047$, $\eta_p^2 = 0.452$).

Post-hoc pairwise comparisons showed that HDSNR produced significantly greater increases in

PAF EC_{50} compared with both placebo and HDSR at specific time points. At 2 h, ΔPAF EC_{50} was

higher in HDSNR versus placebo (mean difference 34.16, 95% CI 4.67 to 63.65, p = .029) and

versus HDSR (27.9, 95% CI 1.9 to 53.9, p = .039). At 3 h, ΔPAF EC_{50} remained elevated relative

to placebo (31.2, 95% CI 7.9 to 54.6, p = .017). Within-condition comparisons showed that

HDSNR elicited a significant rise from baseline at both 2 h (31.2, 95% CI 4.89 to 57.5, p = .027)

and 3 h (29.3, 95% CI 11.9 to 46.7, p = .007). For the HDSR condition, increases were only evident

at 4 h (e.g., 41.1 above baseline, 95% CI 1.17 to 80.9, p = .045).

When collapsed across time, a significant main effect of treatment was also observed

($F_{(4,16)}$ = 6.75, p = .015, η_p^2 = 0.628), driven by a higher mean ΔPAF EC_{50} in HDSNR compared

with placebo (22.04, 95% CI 13.7 to 30.4, p = .001). A significant main effect of time indicated

that ΔPAF EC_{50} rose above baseline at 3 h across treatments (20.16, 95% CI 3.19 to 37.2, p =

.027). For ΔAUC (Figure 2B), repeated-measures ANOVA identified a significant treatment effect

($F_{(4, 16)}$ = 5.784, p = .004, η_p^2 = 0.591). Post-hoc pairwise comparisons showed that HDSNR

produced a greater cumulative change in EC_{50} over 0–4 h compared with placebo (mean difference

95.96, 95% CI 55.06–136.7, p = .002). No other pairwise comparisons were significant.

303 A.

310 B.

Fig. 2. **(A)** Temporal change in EC_{50} values of PAF-induced platelet aggregation in human

platelet-rich plasma across all treatment conditions. Data are presented as mean percentage change

from baseline (ΔC/C EC$_{50}$; n = 5) with error bars representing the standard error of the mean

(SEM). Statistical analysis was performed using a two-factor repeated-measures ANOVA

(treatment $\times$ time). Where significant interactions were detected, Bonferroni-adjusted pairwise

comparisons were applied. *Indicates $p < 0.05$ for significant pairwise differences between

treatments at a given time point. **Indicates $p < 0.05$ for significant main effects of treatment or

time. An increase in EC$_{50}$ reflects a reduction in platelet sensitivity to PAF. **(B)** Boxplots showing

the area-under-the-curve (AUC) for ΔPAF EC$_{50}$ (0–4 h) across all treatment conditions. Boxes

represent the interquartile range (IQR), horizontal lines indicate the median, and whiskers show

the range excluding outliers; circles represent values >1.5 $\times$ IQR identified during outlier

screening. AUC data were analysed using a repeated-measures ANOVA after confirming

normality (Shapiro–Wilk) and sphericity (Mauchly's test). A significant main effect of treatment

was detected ($p < 0.05$), with post-hoc contrasts demonstrating higher ΔAUC in the HDSNR

condition compared with placebo. **Abbreviations:** HDSNR, high-dose stomach non-resistant

capsule contained 0.5 g of SPL; IQR, interquartile range; HDSR, high-dose stomach resistant

capsule contained 0.5 g of SPL; LDSNR, low-dose stomach non-resistant capsule containing 0.25

g of SPL; LDSR, low-dose stomach resistant capsule contained 0.25 g of SPL. PAF, platelet-

activating factor; PLAC, placebo control.

3.4. Postprandial effect of SPL on platelet sensitivity to thrombin

Figure 3 depicts the temporal change in thrombin EC$_{50}$ for each treatment following ingestion

when compared to baseline measurements (t = 0). The placebo did not significantly affect thrombin

EC$_{50}$ at any time in the 4 h postprandial period. Analysis of Δthrombin EC$_{50}$ revealed no significant

treatment $\times$ time interaction ($F_{(16, 64)} = 3.823$, $p = .050$, $\eta_p^2 = 0.489$), indicating that temporal

changes were similar across treatments. When examined independently of time, there was a

significant main effect of treatment ($F(4, 16) = 8.965$, $p = .007$, $\eta_p^2 = 0.691$). Post-hoc pairwise

comparisons showed that Δthrombin EC_{50} was significantly higher following HDSNR compared

with LDSR (mean difference 27.1, 95% CI 10.6–43.6, $p = .008$). A significant main effect of time

was also observed ($F(4, 16) = 16.221$, $p < 0.001$, $\eta_p^2 = 0.802$). Compared with baseline, Δthrombin

EC_{50} increased significantly at 3 h (36.7, 95% CI 10.8–62.6, $p = .014$) and 4 h (47.7, 95% CI 17.0–

78.5, $p = .010$) across treatments. For the ΔAUC analysis, one mild outlier (HDSR) was detected

(Figure 3). Repeated-measures ANOVA identified a significant effect of treatment on thrombin

ΔAUC ($F(4, 16) = 8.555$, $p < 0.001$, $\eta_p^2 = 0.681$). Post-hoc pairwise comparisons indicated that

HDSNR produced a significantly greater cumulative increase in thrombin EC50 over 0–4 h

compared with LDSR (mean difference 122.9, 95% CI 53.9–191.9, $p = .006$). No additional

pairwise differences reached significance.

Fig. 3. (A) Temporal change in EC$_{50}$ values of thrombin-induced platelet aggregation of human

platelet-rich plasma across all treatment conditions. Data are presented as mean percentage change

from baseline (ΔC/C EC_{50}; n = 5) with error bars representing the standard error of the mean

(SEM). Statistical analysis was performed using a two-factor repeated-measures ANOVA

(treatment × time). No significant interaction was detected; however, significant main effects of

treatment and time were observed, with post-hoc pairwise comparisons applied where appropriate.

Higher EC_{50} values indicate reduced platelet sensitivity to thrombin. **(B)** Boxplots showing the

area-under-the-curve (AUC) for Δthrombin EC_{50} (0–4 h) for each treatment. Boxes represent the

interquartile range (IQR), horizontal lines indicate the median, and whiskers show the range

excluding outliers; circles denote values >1.5 × IQR identified during outlier screening. AUC data

were analysed using repeated-measures ANOVA, which revealed a significant main effect of

treatment. Post-hoc pairwise comparisons indicated that HDSNR elicited a greater cumulative

change in thrombin EC50 compared with LDSR. **Abbreviations:** HDSNR, high-dose stomach

non-resistant capsule contained 0.5 g of SPL; IQR, interquartile range; HDSR, high-dose stomach

resistant capsule contained 0.5 g of SPL; LDSNR, low-dose stomach non-resistant capsule

containing 0.25 g of SPL; LDSR, low-dose stomach resistant capsule contained 0.25 g of SPL.

PAF, platelet-activating factor; PLAC, placebo control.

4. Discussion

Activation and aggregation of platelets contribute to the inflammatory and thrombotic

manifestations of atherosclerosis and CVD [5,6,12]. Dysregulated platelet activity also plays an

important role in other pathologies, including type II diabetes mellitus [35] and cancer [36].

Repetitive activation of platelets and plasmatic coagulation during the postprandial period has

further been implicated in the initiation, development, and progression of atherosclerosis [2,21,37].

These mechanisms highlight the importance of identifying bioactive molecules and natural

products capable of attenuating platelet activation, with the aim of developing novel supplements

and nutraceuticals with potential cardioprotective properties. While there are several avenues of

potential research to explore, including dietary components of the Mediterranean diet capable of

reducing postprandial platelet sensitivity to PAF in healthy individuals and patients with metabolic

syndrome [38,39].

Marine-derived polar lipids represent one such promising class of bioactives. Previous in

vitro studies have demonstrated that salmon polar lipid (SPL) extracts contain bioactive molecules

with anti-PAF and anti-thrombin activities [25,27,28]. A broader body of work from our group and

others has shown that marine polar lipids exhibit diverse anti-inflammatory and cardioprotective

effects [17,23,27,31,40,41], including anti-atherogenic actions in platelets and various cell types both

in vitro and *in vivo* [42,43]. While natural antiplatelet nutraceuticals such as FruitFlow™, a water

soluble (lipid-free) tomato-based supplement shown to beneficially affect postprandial ADP-

induced platelet aggregation [44], have reached commercial use, targeted clinical work examining

marine polar lipid preparations remains limited.

In this context, the present pilot study provides the first in vivo indication that SPL

ingestion may modestly reduce platelet sensitivity to both PAF and thrombin in healthy subjects.

Among the five postprandial trials tested, the high-dose non–stomach-resistant capsule (HDSNR)

produced the clearest reductions in platelet sensitivity, with significant increases in EC_{50} for PAF

at 2–3 h and for thrombin at 3–4 h post-ingestion. The stomach-resistant formulation (HDSR)

generated similar but delayed effects, suggesting that the timing of polar lipid release plays a

crucial role in determining the onset of antiplatelet activity. The low-dose capsules produced more

modest or inconsistent responses. Despite the small sample size, these findings support the concept

that SPL-derived polar lipids acutely modulate platelet reactivity, potentially through interactions

with the PAF-R and PAR receptors. The stronger and earlier effect observed with HDSNR is

consistent with more rapid release and absorption of bioactive lipids, whereas the attenuated and

delayed effect of HDSR suggests slower release in the gastrointestinal tract.

Importantly, these antiplatelet effects occurred without measurable alterations in key

haemostatic biomarkers (fibrinogen, PT, APTT, INR). Monitoring such biomarkers is essential

when evaluating novel antiplatelet agents to ensure that modulation of platelet sensitivity does not

translate into increased bleeding risk [45,46]. Notably, the reduction of the sensitivity of platelets

against both PAF and thrombin during both high-dose trials does not seem to affect coagulation

biomarker (Fibrinogen, PT, APTT, and INR). These results further suggest that the observed

favorable postprandial antiplatelet effects against both PAF and thrombin do not postprandially

increase the risk of bleeding, even when supplements containing high doses of the SPL were

administrated during the HDSNR and HDSR trials. These findings support the notion that marine

phospholipid supplements are safe for consumption [31]. However, cumulative intake and long-

term exposure must be monitored by conducting a dietary intervention study to ensure safety.

Plasma fibrinogen, an acute-phase reactant associated with cardiovascular risk and platelet

aggregation [46], also remained unchanged. The absence of fibrinogen fluctuations likely reflects

the healthy status of the cohort, as supported by consistently low CRP values (<5 mg/L) throughout

the study. Similarly, postprandial glucose and lipid levels (TC, HDL-C, LDL-C, TG) remained

stable, which is desirable given that postprandial hyperglycemia and lipemia can augment platelet

reactivity and cardiovascular risk [20,47,48]. The stability of these markers likely reflects the healthy

metabolic profile of participants at baseline.

The earlier and more pronounced antiplatelet response observed in the HDSNR trial

compared with the HDSR trial likely reflects differences in capsule disintegration and bioactive

lipid release. Non-resistant capsules permit immediate release in the stomach, whereas resistant

capsules delay release until later digestive stages. These release profiles may have implications for

optimizing postprandial timing and therapeutic efficacy with further considerations for circadian

rhythms [49,50]. Nonetheless, the overall magnitude of the antiplatelet response was modest and

must be interpreted with caution, as intra- and inter-individual variability may have influenced

outcomes in this small cohort. Platelet function is known to vary with diet, ethnicity, sex, and other

factors [51]. Furthermore, a postprandial assessment is required to determine how long the

postprandial effects lasts, to inform for dosage in further studies.

While consumption of the capsule in this trial appears to be safe and did not increase the

risk of bleeding following acute exposure, further long-term studies are required to confirm these

observations. Furthermore, we did not observe how long the antiplatelet effect would last

postprandially. Therefore, additional research is required to determine whether a repeated dose

schedule is required. Previous studies of omega-3 fatty acid preparations, which carry similar fatty

acids but in neutral forms, have shown that the antiplatelet effects may last up to hours post

ingestion. However, it is difficult to determine whether this would be a similar response using PL

supplements and our findings would suggest that the encapsulation method would be important to

consider.

Additionally, this study used a relatively low (0.25 g) and high-dose (0.5 g) version of the

capsule, similar trials using fish oils high in EPA and DHA known to have antithrombotic effects

previously administered doses in excess of 5g [52]. A conservative amount of fish oil in the form

of polar lipids used was chosen for these trials due to the greater reported bioavailability and

bioactivity of polar lipids. Future work should evaluate higher SPL doses (e.g., 1 g) to better

characterize dose–response relationships. Tolerability was good in this study, with no

gastrointestinal symptoms or vasoconstrictive adverse events reported. However, side effects are

possible and fish oil supplements have been associated with diarrhea, but these side effects tend to

be associated with large doses of fish oil [52]. Fishy breath or belching is also a possible side effect

of fish oil supplement intake. Indeed, the salmon capsules used in this study were not deodorized,

as is common for similar fish supplements. We chose not to undertake this step due to potential

degradation of the lipid content [53]. Therefore, dietary intervention studies should assess for these

common side effects to improve formulation of the capsule.

Lastly, the diet of fish influences the fatty acid and polar lipid composition of the flesh,

which in turn affects the composition of fish oils [54,55]. This opens the field to opportunities for

tailored polar lipid compositions as a therapeutic or as a liposomal carrier [56] for other drugs

through modulation of the diet in aquaculture setting.

5. Conclusions

This is the first placebo-controlled study reporting a modest favorable outcome of the

administration of a novel food supplement containing bioactive SPL, with respect to postprandial

platelet sensitivity against PAF and thrombin and its related cardiovascular risk in healthy human

subjects. This pilot study provides data and the rationale to support the development of further

large long-term trials to confirm these findings in both healthy subjects and cardiovascular patients

to evaluate the long-term effects, safety, tolerability, and cardioprotective properties of this novel

supplement.

Supplementary Materials: Table S1: Participant baseline physical and haematological characteristics; Table S2: Participant baseline biochemical characteristics. Figure S1: Postprandial effect of SPL on the plasma levels of triglycerides, total cholesterol, HDL, and LDL cholesterol and glucose; Figure S2: Postprandial effect of SPL on blood coagulation biomarkers.

Author Contributions: Conceptualization, I.Z., A.T., P.J. and R.L.; methodology, R.L. and A.T.; software, R.L.; validation, P.J., I.Z. and R.L.; formal analysis, A.T. and R.L.; investigation, A.T. and R.L..; resources, P.J.I.Z.; data and curation, R.L. and P.J.; writing—original draft preparation, R.L. and A.T.; writing—review and editing, R.L., A.T., P.J. and I.Z.; visualization, A.T., R.L. and P.J.; supervision, P.J. and I.Z.; project administration. A.T. and R.L.; funding acquisition, P.J., R.L. and I.Z. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by Enterprise Ireland (grant reference: IP 2017 0518).

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Faculty of Science & Engineering Research Ethics Committee of the University of Limerick (UL Ethics Approval Number: 2017_10_10_S&E).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data is available from the authors without reservation.

Acknowledgments: The authors are grateful to the volunteers who took part in the study, to Elaine Ahern for her phlebotomy support, and to Dr Emmet Kerrin at Treaty Medical, Limerick. The authors acknowledge the support of Lifes2good, Marine Harvest, and Mowi Ireland for their contributions. We would also like to thank the Departments of Physical Education and Sports Science and the Biological Sciences at the University of Limerick, Ireland, for their continued support. Finally, we are grateful to Patricia Kennedy, Carolyn Holt, and colleagues at the laboratories of the University Hospital Limerick for analytical support.

Conflicts of Interest: The authors declare no conflict of interest. The grant providers, Enterprise Ireland IP 2017 0508, had no role in the design of the study, in the collection, analyses or interpretation of the data or in the writing of the manuscript.

References:

1. P. Libby; Ridker, P.M.; Hansson, G.K. Inflammation in Atherosclerosis: From Pathophysiology to Practice. *J Am Coll Cardiol* 2009, *54*, 2129-2138, doi:https://doi.org/10.1016/j.jacc.2009.09.009.
2. R. Lordan; Tsoupras, A.; Zabetakis, I. Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents. *Blood Reviews* 2021, *45*, 100694, doi:https://doi.org/10.1016/j.blre.2020.100694.
3. P. Libby. Inflammation in Atherosclerosis—No Longer a Theory. *Clinical Chemistry* 2020, *67*, 131-142, doi:10.1093/clinchem/hvaa275.
4. P. Kong; Cui, Z.-Y.; Huang, X.-F.; Zhang, D.-D.; Guo, R.-J.; Han, M. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. *Signal Transduction and Targeted Therapy* 2022, *7*, 131, doi:10.1038/s41392-022-00955-7.
5. K.Y. Stokes; Granger, D.N. Platelets: a critical link between inflammation and microvascular dysfunction. *The Journal of Physiology* 2012, *590*, 1023-1034, doi:10.1113/jphysiol.2011.225417.
6. R. Huilcaman; Venturini, W.; Fuenzalida, L.; Cayo, A.; Segovia, R.; Valenzuela, C.; Brown, N.; Moore-Carrasco, R. Platelets, a key cell in inflammation and atherosclerosis progression. *Cells* 2022, *11*, doi:10.3390/cells11061014.

7. C. Bakogiannis; Sachse, M.; Stamatelopoulos, K.; Stellos, K. Platelet-derived chemokines in inflammation and atherosclerosis. *Cytokine* 2019, *122*, 154157, doi:https://doi.org/10.1016/j.cyto.2017.09.013.

8. N.E. Tsopanoglou; Maragoudakis, M.E. Thrombin's central role in angiogenesis and pathophysiological processes. *European Cytokine Network* 2009, *20*, 171-179.

9. Z. Li; Delaney, M.K.; O'Brien, K.A.; Du, X. Signaling during platelet adhesion and activation. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2010, *30*, 2341-2349, doi:10.1161/ATVBAHA.110.207522.

10. G.A. Zimmerman; McIntyre, T.M.; Prescott, S.M.; Stafforini, D.M. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. *Critical care medicine* 2002, *30*, S294-S301.

11. R. Lordan; Tsoupras, A.; Zabetakis, I.; Demopoulos, A.C. Forty years since the structural elucidation of platelet-activating factor (PAF): Historical, current, and future research perspectives. *Molecules* 2019, *24*, doi:doi:10.3390/molecules24234414.

12. N. Jaberi; Soleimani, A.; Pashirzad, M.; Abdeahad, H.; Mohammadi, F.; Khoshakhlagh, M.; Khazaei, M.; Ferns, G.A.; Avan, A.; Hassanian, S.M. Role of thrombin in the pathogenesis of atherosclerosis. *Journal of Cellular Biochemistry* 2019, *120*, 4757-4765, doi:10.1002/jcb.27771.

13. F.K. Keating; Schneider, D.J. The influence of platelet activating factor on the effects of platelet agonists and antiplatelet agents in vitro. *Journal of Thrombosis and Thrombolysis* 2009, *28*, 38-45, doi:10.1007/s11239-008-0239-5.

14. V.O. Melnikova; Villares, G.J.; Bar-Eli, M. Emerging roles of PAR-1 and PAFR in melanoma metastasis. *Cancer Microenvironment* 2008, *1*, 103-111, doi:10.1007/s12307-008-0002-7.

15. E. Yu; Malik, V.S.; Hu, F.B. Cardiovascular disease prevention by diet modification: JACC Health Promotion Series. *Journal of the American College of Cardiology* 2018, *72*, 914-926, doi:doi:10.1016/j.jacc.2018.02.085.

16. P. Wang; Song, M.; Eliassen, A.H.; Wang, M.; Fung, T.T.; Clinton, S.K.; Rimm, E.B.; Hu, F.B.; Willett, W.C.; Tabung, F.K., et al. Optimal dietary patterns for prevention of chronic disease. *Nature Medicine* 2023, *29*, 719-728, doi:10.1038/s41591-023-02235-5.

17. T. Nomikos; Fragopoulou, E.; Antonopoulou, S.; Panagiotakos, D.B. Mediterranean diet and platelet-activating factor; a systematic review. *Clinical Biochemistry* 2018, https://doi.org/10.1016/j.clinbiochem.2018.08.004, doi:https://doi.org/10.1016/j.clinbiochem.2018.08.004.

18. J.H. O'Keefe; Bell, D.S.H. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. *The American Journal of Cardiology* 2007, *100*, 899-904, doi:http://dx.doi.org/10.1016/j.amjcard.2007.03.107.

19. E.J.P. de Koning; Rabelink, T.J. Endothelial function in the post-prandial state. *Atherosclerosis Supplement* 2002, *3*, 11-16, doi:http://dx.doi.org/10.1016/S1567-5688(01)00008-3.

20. D.A. Hyson; Paglieroni, T.G.; Wun, T.; Rutledge, J.C. Postprandial Lipemia is Associated With Platelet and Monocyte Activation and Increased Monocyte Cytokine Expression in Normolipemic Men. *Clinical and Applied Thrombosis/Hemostasis* 2002, *8*, 147-155, doi:10.1177/107602960200800211.

21. A. Mikellidi; Nomikos, T. Postprandial activation of platelets as a possible mechanism for the development of atherosclerosis. *Hellenic Journal of Atherosclerosis* 2016, *7*.

22. M.N. Xanthopoulou; Kalathara, K.; Melachroinou, S.; Arampatzi-Menenakou, K.; Antonopoulou, S.; Yannakoulia, M.; Fragopoulou, E. Wine consumption reduced postprandial platelet sensitivity against platelet activating factor in healthy men. *European Journal of Nutrition* 2017, *56*, 1485-1492, doi:doi:10.1007/s00394-016-1194-0.

23. C. Caffrey; Leamy, A.; O'Sullivan, E.; Zabetakis, I.; Lordan, R.; Nasopoulou, C. Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids. *Marine Drugs* 2023, *21*, 549.

24. R. Tummala; Ghosh, R.K.; Jain, V.; Devanabanda, A.R.; Bandyopadhyay, D.; Deedwania, P.; Aronow, W.S. Fish Oil and Cardiometabolic Diseases: Recent Updates and Controversies. *The American Journal of Medicine* 2019, *132*, 1153-1159, doi:https://doi.org/10.1016/j.amjmed.2019.04.027.

25. A. Tsoupras; Lordan, R.; Shiels, K.; Saha, S.K.; Nasopoulou, C.; Zabetakis, I. In vitro antithrombotic properties of salmon (*Salmo salar*) phospholipids in a novel food-grade extract. *Marine Drugs* 2019, *17*, 62, doi:https://doi.org/10.3390/md17010062.

26. A.S. Chopra; Lordan, R.; Horbańczuk, O.K.; Atanasov, A.G.; Chopra, I.; Horbańczuk, J.O.; Jóźwik, A.; Huang, L.; Pirgozliev, V.; Banach, M., et al. The current use and evolving landscape of nutraceuticals. *Pharma. Res.* 2022, *175*, 106001, doi:https://doi.org/10.1016/j.phrs.2021.106001.

27. A. Tsoupras; O'Keeffe, E.; Lordan, R.; Redfern, S.; Zabetakis, I. Bioprospecting for antithrombotic polar lipids from salmon, herring, and boarfish by-products. *Foods* 2019, *8*, 416, doi:https://doi.org/10.3390/foods8090416.

28. A. Tsoupras; Lordan, R.; Demuru, M.; Shiels, K.; Saha, S.K.; Nasopoulou, C.; Zabetakis, I. Structural elucidation of Irish organic farmed salmon (*Salmo salar*) polar lipids with antithrombotic activities. *Marine Drugs* 2018, *16*, 176, doi:https://doi.org/10.3390/md16060176.

29. H. Cao; Chen, S.-F.; Wang, Z.-C.; Dong, X.-J.; Wang, R.-R.; Lin, H.; Wang, Q.; Zhao, X.-J. Intervention of 4% salmon phospholipid on metabolic syndrome in mice based on colonic lipidomics analysis. *Journal of the Science of Food and Agriculture* 2022, *102*, 3088-3098, doi:https://doi.org/10.1002/jsfa.11649.

30. R. Adili; Hawley, M.; Holinstat, M. Regulation of platelet function and thrombosis by omega-3 and omega-6 polyunsaturated fatty acids. *Prostaglandins & Other Lipid Mediators* 2018, *139*, 10-18, doi:https://doi.org/10.1016/j.prostaglandins.2018.09.005.

31. R. Lordan; Redfern, S.; Tsoupras, A.; Zabetakis, I. Inflammation and cardiovascular disease: are marine phospholipids the answer? *Food Funct.* 2020, *11*, 2861 - 2885, doi:https://doi.org/10.1039/C9FO01742A.

32. E.M. Bachmair; Ostertag, L.M.; Zhang, X.; de Roos, B. Dietary manipulation of platelet function. *Pharmacology & Therapeutics* 2014, *144*, 97-113, doi:https://doi.org/10.1016/j.pharmthera.2014.05.008.

33. Health Service Executive Ireland. Healthy food for life guidelines. Availabe online: http://www.hse.ie/eng/about/Who/healthwellbeing/Our-Priority-Programmes/HEAL/Healthy-Eating-Guidelines/ (accessed on accessed on 17 January 2018).

34. A. Tsoupras; Zabetakis, I.; Lordan, R. Platelet aggregometry assay for evaluating the effects of platelet agonists and antiplatelet compounds on platelet function *in vitro*. *MethodsX* 2019, *6*, 63-70, doi:https://doi.org/10.1016/j.mex.2018.12.012.

35. L. Pretorius; Thomson, G.J.A.; Adams, R.C.M.; Nell, T.A.; Laubscher, W.A.; Pretorius, E. Platelet activity and hypercoagulation in type 2 diabetes. *Cardiovascular Diabetology* 2018, *17*, 141, doi:10.1186/s12933-018-0783-z.

36. A. Contursi; Grande, R.; Dovizio, M.; Bruno, A.; Fullone, R.; Patrignani, P. Platelets in cancer development and diagnosis. *Biochem Soc Trans* 2018, *46*, 1517-1527, doi:10.1042/bst20180159.

37. A.K. Duttaroy. Postprandial activation of hemostatic factors: Role of dietary fatty acids. *Prostaglandins, Leukotrienes and Essential Fatty Acids* 2005, *72*, 381-391, doi:10.1016/j.plefa.2005.03.003.

38. E. Fragopoulou; Detopoulou, P.; Nomikos, T.; Pliakis, E.; Panagiotakos, D.B.; Antonopoulou, S. Mediterranean wild plants reduce postprandial platelet aggregation in patients with metabolic syndrome. *Metabolism* 2012, *61*, 325-334.

39. M.N. Xanthopoulou; Kalathara, K.; Melachroinou, S.; Arampatzi-Menenakou, K.; Antonopoulou, S.; Yannakoulia, M.; Fragopoulou, E. Wine consumption reduced postprandial platelet sensitivity against platelet activating factor in healthy men. *European Journal of Nutrition* 2016, http://dx.doi.org/10.1007/s00394-016-1194-0, 1-8, doi:http://dx.doi.org/10.1007/s00394-016-1194-0.

40. F. Petsini; Ntzouvani, A.; Detopoulou, M.; Papakonstantinou, V.D.; Kalogeropoulos, N.; Fragopoulou, E.; Nomikos, T.; Kontogianni, M.D.; Antonopoulou, S. Consumption of Farmed Fish, Fed with an Olive-Pomace Enriched Diet, and Its Effect on the Inflammatory, Redox, and Platelet-Activating Factor Enzyme Profile of Apparently Healthy Adults: A Double-Blind Randomized Crossover Trial. *Foods* 2022, *11*, 2105.

41. E. Sioriki; Smith, T.K.; Demopoulos, C.A.; Zabetakis, I. Structure and cardioprotective activities of polar lipids of olive pomace, olive pomace-enriched fish feed and olive pomace fed gilthead sea bream (*Sparus aurata*). *Food Res. Int.* 2016, *83*, 143-151, doi:http://dx.doi.org/10.1016/j.foodres.2016.03.015.

42. C. Nasopoulou; Karantonis, H.C.; Perrea, D.N.; Theocharis, S.E.; Iliopoulos, D.G.; Demopoulos, C.A.; Zabetakis, I. In vivo anti-atherogenic properties of cultured gilthead sea bream (*Sparus aurata*) polar lipid extracts in hypercholesterolaemic rabbits. *Food Chemistry* 2010, *120*, 831-836, doi:http://dx.doi.org/10.1016/j.foodchem.2009.11.023.

43. C. Nasopoulou; Tsoupras, A.B.; Karantonis, H.C.; Demopoulos, C.A.; Zabetakis, I. Fish polar lipids retard atherosclerosis in rabbits by down-regulating PAF biosynthesis and up-regulating PAF catabolism. *Lipids in Health and Disease* 2011, *10*, 1-18, doi:doi:10.1186/1476-511X-10-213.

44. N. O'Kennedy; Crosbie, L.; van Lieshout, M.; Broom, J.I.; Webb, D.J.; Duttaroy, A.K. Effects of antiplatelet components of tomato extract on platelet function in vitro and ex vivo: a time-course cannulation study in healthy humans. *The American Journal of Clinical Nutrition* 2006, *84*, 570-579.

45. J.M. Walenga; Hoppensteadt, D.A. Monitoring the new antithrombotic drugs. In Proceedings of Seminars in Thrombosis and Hemostasis; pp. 683-695.

46. W.B. Kannel. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. *Lipids* 2005, *40*, 1215-1220, doi:10.1007/s11745-005-1488-8.

47. D. Hyson; Rutledge, J.C.; Berglund, L. Postprandial lipemia and cardiovascular disease. *Current Atherosclerosis Reports* 2003, *5*, 437-444, doi:http://dx.doi.org/10.1007/s11883-003-0033-y.

48. M. Shimodaira; Niwa, T.; Nakajima, K.; Kobayashi, M.; Hanyu, N.; Nakayama, T.
Correlation between mean platelet volume and blood glucose levels after oral glucose
loading in normoglycemic and prediabetic Japanese subjects. *Journal of Diabetes*
Investigation 2014, *5*, 66-71, doi:10.1111/jdi.12117.
49. C.T. Butler; Rodgers, A.M.; Curtis, A.M.; Donnelly, R.F. Chrono-tailored drug delivery
systems: recent advances and future directions. *Drug Delivery and Translational*
Research 2024, *14*, 1756-1775, doi:10.1007/s13346-024-01539-4.
50. G.K. Paschos; Lordan, R.; FitzGerald, G.A. Intersection of sex and circadian Biology.
Current Opinion in Physiology 2025.
51. C.H. Miller; Rice, A.S.; Garrett, K.; Stein, S.F. Gender, race and diet affect platelet
function tests in normal subjects, contributing to a high rate of abnormal results. *British*
journal of haematology 2014, *165*, 842-853, doi:10.1111/bjh.12827.
52. C. Skarke; Alamuddin, N.; Lawson, J.A.; Li, X.; Ferguson, J.F.; Reilly, M.P.; FitzGerald,
G.A. Bioactive products formed in humans from fish oils. *Journal of Lipid research*
2015, *56*, 1808-1820.
53. V. Fournier; Destaillats, F.; Juanéda, P.; Dionisi, F.; Lambelet, P.; Sébédio, J.-L.;
Berdeaux, O. Thermal degradation of long-chain polyunsaturated fatty acids during
deodorization of fish oil. *European Journal of Lipid Science and Technology* 2006, *108*,
33-42, doi:https://doi.org/10.1002/ejlt.200500290.
54. B.K. Hundal; Liland, N.S.; Rosenlund, G.; Bou, M.; Stubhaug, I.; Sissener, N.H.
Increasing dietary n-6 fatty acids while keeping n-3 fatty acids stable decreases EPA in
polar lipids of farmed Atlantic salmon (Salmo salar). *British Journal of Nutrition* 2021,
125, 10-25, doi:10.1017/S0007114520002494.
55. K. Kousoulaki; Østbye, T.-K.K.; Krasnov, A.; Torgersen, J.S.; Mørkøre, T.; Sweetman, J.
Metabolism, health and fillet nutritional quality in Atlantic salmon (Salmo salar) fed diets
containing n-3-rich microalgae. *Journal of Nutritional Science* 2015, *4*, e24,
doi:10.1017/jns.2015.14.
56. M. Gerlei; Pruvost, L.; Linder, M. Salmon and krill phospholipids: Two nanocarriers with
interesting physico-chemical properties. *Biochimie* 2025, *239*, 19-29,
doi:https://doi.org/10.1016/j.biochi.2025.09.010.
705